CRVSHealthcare · BiotechnologyThe 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. hold a median 12-month price target of $32 — +225.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Corvus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (83): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CRVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +225.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Apr 2026 | Goldman Sachs | Initiates | Buy | $40 |
| 17 Apr 2026 | Goldman Sachs | Initiates | Buy | — |
| 13 Mar 2026 | Oppenheimer | Reiterates | Outperform | — |
| 22 Jan 2026 | Jefferies | Maintains | Buy | — |
| 21 Jan 2026 | Barclays | Maintains | Overweight | — |
| 21 Jan 2026 | Oppenheimer | Maintains | Outperform | — |
| 20 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Oct 2025 | Barclays | Initiates | Overweight | — |
| 20 May 2025 | Mizuho | Maintains | Outperform | — |
| 9 May 2025 | Oppenheimer | Reiterates | Outperform | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Mar 2025 | Oppenheimer | Maintains | Outperform | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Jan 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 13 Nov 2024 | Oppenheimer | Reiterates | Outperform | — |
| 16 Sept 2024 | Ladenburg Thalmann | Maintains | Buy | — |
| 7 May 2024 | Oppenheimer | Maintains | Outperform | — |
| 1 Apr 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 Mar 2024 | Mizuho | Maintains | Neutral | — |
| 20 Mar 2024 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CRVS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Corvus Pharmaceuticals, Inc. returned +26.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 25% of US stocks
Cheaper than 86% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 26% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Corvus Pharmaceuticals, Inc. has a market value of $860.6M and an enterprise value of $646.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$54.1M.
Diluted earnings per share, trailing twelve months: $−0.61.
Free cash flow in the twelve months to 30 June 2026: −$45.2M.
Trailing P/E: −52.0×; forward P/E: −9.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Corvus Pharmaceuticals, Inc. employs 37 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Corvus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Corvus Pharmaceuticals announced a conference call and webcast for November 5, 2026, at 4:30 p.m. ET to provide a business update and report its third-quarter 2026 financial results.
Why it matters — CRVS watchers can hear the company’s business update and review its quarterly financial results on the scheduled call.
Corvus Pharmaceuticals announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for patients with hidradenitis suppurativa. The trial will evaluate the drug in this additional indication.
Why it matters — This expands soquelitinib's clinical pipeline into a new disease area, offering CRVS watchers progress on a potential additional therapeutic application.
Corvus Pharmaceuticals announced that members of its leadership team will hold one-on-one meetings with investors and participate in a fireside chat presentation at the 2026 Cantor Global Healthcare Conference in New York, NY, on September 10, 2026 at 1:00 pm ET.
Why it matters — A CRVS watcher would care because the company's participation at a major healthcare conference offers potential visibility and engagement opportunities with investors.
Corvus Pharmaceuticals announced the publication in the journal Blood of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma. The data support the ongoing registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, as well as trials in atopic dermatitis, hidradenitis suppurativa, and asthma.
Why it matters — The publication of final Phase 1 data in a peer-reviewed journal lends validation to soquelitinib's novel ITK inhibition mechanism and supports the company's ongoing clinical development across multiple indications.
Seeking Alpha published the transcript of Corvus Pharmaceuticals' (CRVS) Q2 2026 earnings call. The item consists solely of the earnings call transcript headline and source.
Why it matters — A CRVS watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly results and management discussion.
The 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. have a median 12-month price target of $32, with estimates ranging from $27 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Corvus Pharmaceuticals, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corvus Pharmaceuticals, Inc. 55 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Corvus Pharmaceuticals, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (83 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +225.5% from the last close, and Ticker Nerd's factor model ranks Corvus Pharmaceuticals, Inc. 55 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Corvus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $42 over the next 12 months.
Corvus Pharmaceuticals, Inc. returned +26.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026". Corvus Pharmaceuticals announced a conference call and webcast for November 5, 2026, at 4:30 p.m. ET to provide a business update and report its third-quarter 2026 financial results.
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation, signaling, and function. Its pipeline includes soquelitinib, a lead ITK inhibitor, along with other programs such as anti-CD73, A2AR, A2BR, and anti-CXCR2 approaches. The company’s research spans solid tumors, T-cell lymphomas, autoimmune disorders, allergic conditions, and infectious diseases. Corvus Pharmaceuticals Inc. is positioned in the biotechnology sector as a development-stage company advancing novel drug candidates through clinical evaluation, with a business model built around drug discovery, clinical development, and scientific partnerships.
CEO Dr. Richard A. Miller M.D. · 37 employees · United States · https://www.corvuspharma.com
